BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29764506)

  • 1. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
    Peng J; Dong C; Wang C; Li W; Yu H; Zhang M; Zhao Q; Zhu B; Zhang J; Li W; Wang F; Wu Q; Zhou W; Yuan Y; Qiu M; Chen G
    Cancer Commun (Lond); 2018 May; 38(1):22. PubMed ID: 29764506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
    Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
    Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
    Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
    Kelly C; Bhuva N; Harrison M; Buckley A; Saunders M
    Eur J Cancer; 2013 Jul; 49(10):2303-10. PubMed ID: 23583220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
    Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin JE; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
    ESMO Open; 2022 Jun; 7(3):100427. PubMed ID: 35798468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
    Upshaw JN; O'Neill A; Carver JR; Dimond EP; Denlinger CS; Kircher SM; Wagner LI; Ky B; Brell JM
    Clin Colorectal Cancer; 2019 Mar; 18(1):44-51. PubMed ID: 30348619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer.
    Polk A; Shahmarvand N; Vistisen K; Vaage-Nilsen M; Larsen FO; Schou M; Nielsen DL
    BMJ Open; 2016 Oct; 6(10):e012798. PubMed ID: 27798021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients.
    Jin X; Bai Y; Gao L; Wu S
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):599-607. PubMed ID: 31203389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
    Saif MW; Garcon MC; Rodriguez G; Rodriguez T
    In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
    Ransom D; Wilson K; Fournier M; Simes RJ; Gebski V; Yip D; Tebbutt N; Karapetis CS; Ferry D; Gordon S; Price TJ
    Ann Oncol; 2014 Jan; 25(1):117-21. PubMed ID: 24299960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.
    Polk A; Vaage-Nilsen M; Vistisen K; Nielsen DL
    Cancer Treat Rev; 2013 Dec; 39(8):974-84. PubMed ID: 23582737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer.
    Schöber C; Papageorgiou E; Harstrick A; Bokemeyer C; Mügge A; Stahl M; Wilke H; Poliwoda H; Hiddemann W; Köhne-Wömpner CH
    Cancer; 1993 Oct; 72(7):2242-7. PubMed ID: 8374883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
    Chakrabarti S; Sara J; Lobo R; Eiring R; Finnes H; Mitchell J; Hartgers M; Okano A; Halfdanarson T; Grothey A
    Clin Colorectal Cancer; 2019 Mar; 18(1):52-57. PubMed ID: 30396850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study).
    Kinos S; Hagman H; Halonen P; Soveri LM; O'Reilly M; Pfeiffer P; Frödin JE; Sorbye H; Heervä E; Liposits G; Kallio R; Ålgars A; Ristamäki R; Salminen T; Bärlund M; Shah CH; McDermott R; Röckert R; Flygare P; Kwakman J; Teske A; Punt C; Glimelius B; Österlund P
    Acta Oncol; 2024 May; 63():248-258. PubMed ID: 38698698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoropyrimidine-Associated Cardiotoxicity.
    Kanduri J; More LA; Godishala A; Asnani A
    Cardiol Clin; 2019 Nov; 37(4):399-405. PubMed ID: 31587781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
    Ma WW; Saif MW; El-Rayes BF; Fakih MG; Cartwright TH; Posey JA; King TR; von Borstel RW; Bamat MK
    Cancer; 2017 Jan; 123(2):345-356. PubMed ID: 27622829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
    Karakulak UN; Aladağ E; Maharjan N; Övünç K
    Turk Kardiyol Dern Ars; 2016 Jan; 44(1):71-4. PubMed ID: 26875134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiotoxicity induced by 5-fluorouracil or capecitabine].
    Jensen SA; Baeksgaard L; Petersen LN; Reiter L; Sørensen JB
    Ugeskr Laeger; 2010 Jan; 172(1):48-51. PubMed ID: 20056096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
    Kwakman JJ; Simkens LH; Mol L; Kok WE; Koopman M; Punt CJ
    Eur J Cancer; 2017 May; 76():93-99. PubMed ID: 28286287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoropyrimidine-associated cardiotoxicity: revisited.
    Saif MW; Shah MM; Shah AR
    Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.